US Patent 11028182 Antigen-binding constructs targeting HER2
Patent 11028182 was granted and assigned to Zymeworks Inc. on June, 2021 by the United States Patent and Trademark Office.
All edits
Described herein are high affinity antigen binding constructs, e.g., antibodies, directed to the ECD2 domain of HER2. The antigen-binding constructs comprise at least one antigen-binding polypeptide construct that binds to ECD2 of HER2 (HER2 ECD2) with increased affinity compared to a wild-type 2C4 antibody. Such antigen-binding polypeptide constructs comprise one or more amino acid modifications in the framework region and/or CDRs compared to the amino acid sequence of a wild-type 2C4 antibody that increase affinity of the antigen-binding polypeptide construct for ECD2 by 2-fold or greater. The antigen-binding constructs can inhibit the growth of HER2-expressing breast cancer cells and gastric cancer cells. Antigen-binding constructs in biparatopic format are internalized in HER2-expressing cells.
US Patent 11028182 Antigen-binding constructs targeting HER2
Find more entities like US Patent 11028182 Antigen-binding constructs targeting HER2
